Nov 25 (Reuters) - Merit Medical Systems Inc MMSI.O:
MERIT MEDICAL’S WRAPSODY WAVE TRIAL EXCEEDS PERFORMANCE GOALS FOR ARTERIOVENOUS GRAFT (AVERAGE) PATIENTS
MERIT MEDICAL SYSTEMS INC - WRAPSODY DEVICE SHOWS 81.4% EFFICACY IN WAVE TRIAL
MERIT MEDICAL SYSTEMS INC - 95.4% OF AVERAGE PATIENTS FREE FROM ADVERSE EVENTS IN WAVE TRIAL
MERIT MEDICAL SYSTEMS INC - WRAPSODY DEVICE NOT APPROVED FOR COMMERCIAL DISTRIBUTION IN U.S.
Source text: ID:nGNX9HqrWP
Further company coverage: MMSI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.